Richard Joseph Auchus, MD, PhD – Program Chair
University of Michigan
Ann Arbor, MI
Phyllis Witzel Speiser, MD
Donald and Barbara Zucker School of Medicine/Northwell
Hempstead, NY
Anand Vaidya, MD, MMSc
Brigham and Women’s Hospital
Boston, MA
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
- Richard Joseph Auchus, MD, PhD:
Consultant - Quest Diagnostics; Corcept Therapeutics; Novartis Pharmaceuticals; Xeris Pharmaceuticals; Crinetics Pharmaceuticals; Adrenas Therapeutics; PhaseBio Pharmaceuticals; Novo Nordisk; Neurocrine Biosciences; Recordati Rare Diseases; H Lundbeck A/S Takeda; Development Center Americas, Inc
Contracted Research - Novartis Pharmaceuticals Neurocrine Biosciences Spruce Biosciences Corcept Therapeutics Diurnal, LTD Sparrow Pharmaceuticals
- Phyllis Witzel Speiser, MD:
Consultant - Member, Adrenas Therapeutics Gene Therapy Data Safety Monitoring Committee;
Research Funding - Neurocrine Phase 3 Site investigator for Pediatric Crinecerfont Trial
- Anand Vaidya, MS, MMSc:
Consultant - Mineralys (ended Oct 2022) Corcept Pharmaceuticals (ended Jan 2022) HRA Pharma (ended Jan 2022)
The following faculty reported no relevant financial relationships:
The following committee member who planned and reviewed content for this activity reported relevant financial relationships:
Athanasios Bikas, MD
Brigham and Women’s Hospital
Brookline, MA
The following member who reviewed content for this activity reported relevant financial relationships:
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.